These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33183271)

  • 1. The value of haematological parameters and serum tumour markers for predicting KRAS mutations in 784 Chinese colorectal cancer patients: a retrospective analysis.
    Cao Y; Gu J; Yan L; Deng S; Mao F; Cai W; Li H; Liu X; Wang J; Wu K; Cai K
    BMC Cancer; 2020 Nov; 20(1):1099. PubMed ID: 33183271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of
    Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
    Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
    Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
    Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
    Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations.
    Li W; Qiu T; Ling Y; Guo L; Li L; Ying J
    Oncotarget; 2015 Nov; 6(37):39607-13. PubMed ID: 26530529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
    Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
    Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of KRAS Mutation Status Prediction Model for Colorectal Cancer Based on Medical Imaging.
    Ren Z; Che J; Wu XW; Xia J
    Comput Math Methods Med; 2021; 2021():3953442. PubMed ID: 34976107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of Haematological Parameters and Tumour Markers in the Prediction of Intestinal Obstruction in 1474 Chinese Colorectal Cancer Patients.
    Cao Y; Ke S; Gu J; Mao F; Yao S; Deng S; Yan L; Wu K; Liu L; Cai K
    Dis Markers; 2020; 2020():8860328. PubMed ID: 32855747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach.
    Taguchi N; Oda S; Yokota Y; Yamamura S; Imuta M; Tsuchigame T; Nagayama Y; Kidoh M; Nakaura T; Shiraishi S; Funama Y; Shinriki S; Miyamoto Y; Baba H; Yamashita Y
    Eur J Radiol; 2019 Sep; 118():38-43. PubMed ID: 31439256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT Texture Analysis: A Potential Biomarker for Evaluating KRAS Mutational Status in Colorectal Cancer.
    Cao J; Wang GR; Wang ZW; Jin ZY
    Chin Med Sci J; 2020 Dec; 35(4):306-314. PubMed ID: 33413746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.